Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients With Metastatic Renal Cell Carcinoma
Human Gene Therapy - United States
doi 10.1089/hum.2008.192
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2010
Authors
Publisher
Mary Ann Liebert Inc